MUSTANG BIO INC (MBIO)
US62818Q2030 - Common Stock
MBIO gets a fundamental rating of 0 out of 10. The analysis compared the fundamentals against 561 industry peers in the Biotechnology industry. MBIO has a bad profitability rating. Also its financial health evaluation is rather negative. MBIO does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
In the past year MBIO has reported negative net income.
In the past year MBIO has reported a negative cash flow from operations.
In the past 5 years MBIO always reported negative net income.
MBIO had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
The Return On Assets of MBIO (-325.54%) is worse than 95.14% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -325.54% | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)-142.59%
ROA(5y)-109.12%
ROE(3y)-14059.8%
ROE(5y)-8466.01%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
MBIO does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
MBIO has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, MBIO has more shares outstanding
MBIO has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
MBIO has an Altman-Z score of -87.95. This is a bad value and indicates that MBIO is not financially healthy and even has some risk of bankruptcy.
MBIO has a worse Altman-Z score (-87.95) than 97.30% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Altman-Z | -87.95 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
MBIO has a Current Ratio of 0.40. This is a bad value and indicates that MBIO is not financially healthy enough and could expect problems in meeting its short term obligations.
With a Current ratio value of 0.40, MBIO is not doing good in the industry: 94.23% of the companies in the same industry are doing better.
A Quick Ratio of 0.40 indicates that MBIO may have some problems paying its short term obligations.
MBIO's Quick ratio of 0.40 is on the low side compared to the rest of the industry. MBIO is outperformed by 93.87% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.4 | ||
| Quick Ratio | 0.4 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 43.82% over the past year.
EPS 1Y (TTM)43.82%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%97.14%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
MBIO is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 15.94% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y90.16%
EPS Next 2Y39.41%
EPS Next 3Y18.89%
EPS Next 5Y15.94%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
MBIO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for MBIO. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
MBIO's earnings are expected to grow with 18.89% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y39.41%
EPS Next 3Y18.89%
5. Dividend
5.1 Amount
No dividends for MBIO!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
MUSTANG BIO INC
NASDAQ:MBIO (1/3/2025, 8:00:01 PM)
Premarket: 0.205 -0.01 (-6.05%)0.2182
+0.01 (+4.45%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners2.16%
Inst Owner Change0%
Ins Owners0.67%
Ins Owner Change0%
Market Cap10.82M
Analysts82.86
Price Target10.2 (4574.61%)
Short Float %0.82%
Short Ratio0.16
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)82.61%
EPS NY rev (1m)0%
EPS NY rev (3m)82.91%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | N/A | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | N/A |
EPS(TTM)-6.32
EYN/A
EPS(NY)-0.36
Fwd EYN/A
FCF(TTM)-0.34
FCFYN/A
OCF(TTM)-0.34
OCFYN/A
SpS0
BVpS-0.17
TBVpS-0.17
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -325.54% | ||
| ROE | N/A | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-142.59%
ROA(5y)-109.12%
ROE(3y)-14059.8%
ROE(5y)-8466.01%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 3.78% | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 0.4 | ||
| Quick Ratio | 0.4 | ||
| Altman-Z | -87.95 |
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)95.65%
Cap/Depr(5y)117.67%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)43.82%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%97.14%
EPS Next Y90.16%
EPS Next 2Y39.41%
EPS Next 3Y18.89%
EPS Next 5Y15.94%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y65.03%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year58.37%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y75.61%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y74.15%
OCF growth 3YN/A
OCF growth 5YN/A